American Diabetes Association
Browse
DC24-0764 SELECT CV outcomes by glycemia-Supplemental Material_Resubmission_24May24.pdf (604.92 kB)

Semaglutide and Cardiovascular Outcomes by Baseline and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT

Download (604.92 kB)
figure
posted on 2024-06-22, 00:10 authored by Ildiko Lingvay, John Deanfield, Steven E. Kahn, Peter E. Weeke, Hermann Toplak, Benjamin M. Scirica, Lars Rydén, Naveen Rathor, Jorge Plutzky, Cristobal Morales, A. Michael Lincoff, Michael Lehrke, Ole Kleist Jeppesen, Grzegorz Gajos, Helen M. Colhoun, Bertrand Cariou, Donna Ryan

OBJECTIVE To evaluate the cardiovascular (CV) effects of semaglutide by baseline and change in HbA1c in a prespecified analysis of SELECT. RESEARCH DESIGN AND METHODS In SELECT, people with overweight/obesity and atherosclerotic CV disease (ASCVD) without diabetes were randomized to weekly semaglutide 2.4 mg or placebo. The primary endpoint of first MACE (CV mortality, non-fatal myocardial infarction [MI], or stroke) was reduced by 20% with semaglutide versus placebo. First MACE, its individual components, expanded MACE (CV mortality, non-fatal MI or stroke, coronary revascularization, or hospitalization for unstable angina), a heart failure (HF) composite (HF hospitalization or urgent medical visit, or CV mortality), coronary revascularization, and all-cause mortality were analyzed by baseline HbA1c subgroup and categories of HbA1c change (<−0.3, −0.3 to 0.3, >0.3 %-points) from baseline to 20 weeks using the intention-to-treat principle using Cox proportional hazards. RESULTS Among 17,604 participants (mean age 61.6 years, 72.3% male), 33.5% had baseline HbA1c of <5.7%, 34.6% had 5.7-<6.0%, and 31.9% had 6.0-<6.5%. The CV risk reduction with semaglutide versus placebo was not shown to be different across baseline HbA1c groups and was consistent with the overall study for all endpoints, except all-cause mortality. CV outcomes were also consistent across subgroups of HbA1c change. CONCLUSIONS In people with overweight or obesity and established ASCVD but not diabetes, semaglutide reduced CV events irrespective of baseline or change in HbA1c. Thus, semaglutide is expected to confer CV benefits in people with established ASCVD who are normoglycemic at baseline and/or in those without HbA1c improvements.

Funding

This analysis was funded by Novo Nordisk A/S. Representatives of the sponsor (Novo Nordisk A/S) were involved in: the design and conduct of the analysis; collection, management, analysis and interpretation of the data; and preparation, review, and approval of the manuscript. A medical writer (funded by the sponsor) assisted with editing the manuscript, under the direction of the lead author.

History